News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Taiwan Liposome Company's Liver Cancer Drug Put on Fast Track in China


3/19/2013 10:37:30 AM

by Richard Daverman, PhD

March 18, 2013 -- Lipotecan®, an innovative liver cancer drug developed by Taiwan Liposome Company, was accepted into the SFDA’s Green Path program, a fast-track approval process. TLC said Lipotecan is a new chemical entity with multiple mechanisms of action against tumors that has shown positive results in ex-China Phase II trials. TLC expects to start a China Phase II trial later this year. More details....

Stock Symbol: (TW: 4152)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES